A VARIETY of natural and synthetic colloidal solutions have been used for the reestablishment of the circulation, but experience has emphasized that the ideal fluid for use in hemorrhagic or traumatic shock is blood of an identical grouping. Since methods have not been developed for the stockpiling of blood, it has become readily apparent that a sufficient supply of blood would not be available for emergency use for mass casualties resulting from an atomic attack. The search for a plasma substitute suitable for stockpiling has therefore been intensified in recent years. Polyvinylpyrrolidone, or PVP, is one of the three agents under intensive investigation for this purpose. It is an entirely synthetic product which is water-soluble, hydrophilic, and of high molecular weight. Originally introduced in 1943 by Hecht and Weese,1 it was administered to approximately one-third million German casualties at the Russian front, and a summary of the results of
ALTEMEIER WA, SCHIFF L, GALL EA, et al. PHYSIOLOGICAL AND PATHOLOGICAL EFFECTS OF LONG-TERM POLYVINYLPYRROLIDONE RETENTION. AMA Arch Surg. 1954;69(3):309–314. doi:10.1001/archsurg.1954.01270030037004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.